ISN Journal summaries: effect of pravastatin on ADPKD and 10 years of Kidney International Reports®
Kidney International®
This randomized, double-blind trial evaluated whether pravastatin could slow disease progression in adults with early autosomal dominant polycystic kidney disease (ADPKD) and preserved kidney function.
Researchers followed 150 participants receiving pravastatin or a placebo for two years to assess changes in height-adjusted total kidney volume; they also tracked changes in kidney blood flow and measured GFR.
Pravastatin did not significantly reduce kidney growth or slow declines in kidney blood flow or function compared with placebo. These results suggest that pravastatin does not modify disease progression in adults with early-stage ADPKD.
Kidney International Reports®
Ten years of Kidney International Reports®
This editorial marks the 10th anniversary of Kidney International Reports® (KIR), reflecting its growth into the most highly cited open access journal in nephrology.
Over the past decade, the journal has expanded its global reach, publishing more than 2000 articles from over 65 countries, and surpassing 2 million article views in 2025.
Innovations such as visual abstracts, new article formats, streamlined peer-review pathways, and article-based publishing have improved accessibility and the speed of dissemination.
The authors conclude that KIR now forms a key part of an integrated ISN journal ecosystem designed to accelerate knowledge sharing and advance kidney health worldwide.
